Form 4: Jasper Therapeutics Director Svetlana Lucas Receives Automatic Stock Option Grant

Svetlana Lucas, a director at Jasper Therapeutics, Inc., was granted options to purchase 7,500 shares of common stock at an exercise price of $6.77 per share, effective July 3, 2025.

Summary

• Svetlana Lucas, a Director at Jasper Therapeutics, Inc. (JSPR), was granted stock options to acquire 7,500 shares of Voting Common Stock.
• The options have an exercise price of $6.77 per share.
• The transaction date for this grant was July 3, 2025.
• The options become exercisable on July 3, 2026, and will expire on July 3, 2035.
• This grant was made automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which stipulates that non-employee directors receive an option to purchase 7,500 shares on the date of each annual meeting of stockholders.
• Following this transaction, Svetlana Lucas beneficially owns 7,500 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine compensation event for a director, aligning their interests with the company's performance, and does not indicate any negative operational or financial issues.

Positives

• The grant aligns the director's financial interests with the long-term performance of Jasper Therapeutics, Inc. through equity ownership.
• It represents a standard component of non-employee director compensation, indicating adherence to established corporate governance practices.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

This filing details a routine compensation event for a non-employee director, which is a common practice across publicly traded companies to attract and retain qualified board members and align their interests with shareholders. It does not provide specific insights into broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The automatic grant of stock options to non-employee directors is a widely adopted compensation practice in the biotechnology and pharmaceutical industries, similar to many other sectors.
• While the specific number of shares (7,500) and exercise price ($6.77) are unique to Jasper Therapeutics' compensation policy, the mechanism of granting options as part of annual compensation is consistent with global benchmarks for corporate governance and executive/director remuneration.

Related Party Transactions

• The grant of stock options to Svetlana Lucas, a director of Jasper Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, potentially encouraging decisions that benefit long-term stock performance.
• Director (Svetlana Lucas): Receives equity-based compensation, providing a financial incentive tied to the company's stock performance.

Key Dates

Keywords

Jasper Therapeutics, JSPR, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership